Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Part of paid clinical trials in Portland, Oregon.

Sponsor
OHSU Knight Cancer Institute
Study ID
NCT03270059
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Central Nervous System Neoplasm
  • Cranial Nerve Disorder
  • Metastatic Malignant Neoplasm in the Brain

Eligibility Criteria

Sex
ALL
Age
10 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ferumoxytol — DRUG
    Given IV
  • Gadolinium — DRUG
    Given IV
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI

Study Details

This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.

Key Dates

Start date
Oct 6, 2017
Status verified
Feb 2026
Primary completion
Dec 15, 2027
Completion
Dec 15, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Group I (gadolinium, ferumoxytol, MRI)
    Patients receive gadolinium IV and then ferumoxytol IV and undergo MRI over 60 minutes on day 1.
  • Experimental: Group II (ferumoxytol, gadolinium, MRI)
    Patients receive ferumoxytol IV and then gadolinium IV and undergo MRI over 60 minutes on day 1.

Primary Outcome Measure

Visualization of normal vasculature [ Time Frame: Up to 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
OHSU Knight Cancer InstitutePortlandOregon97239
Ramon Barajas, MD
[email protected]
503-418-0990
Ramon Barajas, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Portland, OR

By research site
OHSU Knight Cancer Institute· Portland, OR

Related Studies